Journal article
Effect of vitamin D3 on self-perceived fatigue: A double-blind randomized placebo-controlled trial.
- Nowak A aDepartment of Internal Medicine bInstitute for Clinical Chemistry, University Hospital Zurich and University of Zurich cDivision of Endocrinology, Diabetology and Clinical Nutrition dDepartment of Geriatrics, University Hospital Zurich, Zurich eDepartment of Internal Medicine, Spital Linth, Uznach, Switzerland.
- Boesch L
- Andres E
- Battegay E
- Hornemann T
- Schmid C
- Bischoff-Ferrari HA
- Suter PM
- Krayenbuehl PA
- 2016-12-30
Published in:
- Medicine. - 2016
Administration, Oral
Adult
Cholecalciferol
Double-Blind Method
Fatigue
Female
Humans
Male
Self Report
Vitamin D
Vitamin D Deficiency
Vitamins
Young Adult
English
BACKGROUND
Vitamin D deficiency is frequent and has been associated with fatigue in uncontrolled trials.
METHODS
This is the first double-blind placebo-controlled clinical trial to investigate the efficacy of per os vitamin D3 (cholecalciferol) in treating fatigue among otherwise healthy persons with low serum 25-hydroxyvitamin D (25(OH)D) levels. We enrolled 120 individuals (mean age 29 ± 6 years, 53% women) presenting with fatigue and vitamin D deficiency (serum 25(OH)D < 20 μg/L). Participants were randomized to a single oral dose of 100,000 units of vitamin D or placebo. The primary endpoint was intra-individual change in the fatigue assessment scale (FAS) at 4 weeks after treatment.
RESULT
The mean age of the participants was 29 ± 6 years, 53% were women. Mean FAS decreased significantly more in the vitamin D group (-3.3 ± 5.3; 95% confidence interval [CI] for change -14.1 to 4.1) compared with placebo (-0.8 ± 5.3; 95% CI for change -9.0 to 8.7); (P = 0.01). Amelioration of fatigue was reported more frequently in vitamin D than in placebo group (42 [72%] vs. 31 [50%]; P = 0.01; odds ratio [OR] 2.63, 95% CI for OR 1.23-5.62). Among all participants, improvement in fatigue score correlated with the rise in 25(OH)D level (R = -0.22, P = 0.02).
CONCLUSION
Vitamin D treatment significantly improved fatigue in otherwise healthy persons with vitamin D deficiency.This study was registered at the www.ClinicalTrials.gov Protocol ID NCT02022475.
Vitamin D deficiency is frequent and has been associated with fatigue in uncontrolled trials.
METHODS
This is the first double-blind placebo-controlled clinical trial to investigate the efficacy of per os vitamin D3 (cholecalciferol) in treating fatigue among otherwise healthy persons with low serum 25-hydroxyvitamin D (25(OH)D) levels. We enrolled 120 individuals (mean age 29 ± 6 years, 53% women) presenting with fatigue and vitamin D deficiency (serum 25(OH)D < 20 μg/L). Participants were randomized to a single oral dose of 100,000 units of vitamin D or placebo. The primary endpoint was intra-individual change in the fatigue assessment scale (FAS) at 4 weeks after treatment.
RESULT
The mean age of the participants was 29 ± 6 years, 53% were women. Mean FAS decreased significantly more in the vitamin D group (-3.3 ± 5.3; 95% confidence interval [CI] for change -14.1 to 4.1) compared with placebo (-0.8 ± 5.3; 95% CI for change -9.0 to 8.7); (P = 0.01). Amelioration of fatigue was reported more frequently in vitamin D than in placebo group (42 [72%] vs. 31 [50%]; P = 0.01; odds ratio [OR] 2.63, 95% CI for OR 1.23-5.62). Among all participants, improvement in fatigue score correlated with the rise in 25(OH)D level (R = -0.22, P = 0.02).
CONCLUSION
Vitamin D treatment significantly improved fatigue in otherwise healthy persons with vitamin D deficiency.This study was registered at the www.ClinicalTrials.gov Protocol ID NCT02022475.
- Language
-
- English
- Open access status
- gold
- Identifiers
-
- DOI 10.1097/MD.0000000000005353
- PMID 28033244
- Persistent URL
- https://susi.usi.ch/global/documents/11534
Statistics
Document views: 27
File downloads: